Functional Interaction of APP-CTF with G-alphaS in Brain
About the Research Project
Program
Award Type
Pilot
Award Amount
$150,000
Active Dates
July 01, 2012 - June 30, 2014
Grant ID
A2012386
Goals
Dr. Angèle Parent and her team’s research efforts focus on understanding the molecular and cellular mechanisms associated with development of Alzheimer’s disease. In this project, they are using transgenic mouse and cell culture techniques to study the function a protein that is suspected to contribute to the pathogenesis. The ultimate goal is to develop novel therapeutic strategies that are applicable to humans to fight this devastating disorder.
Summary
Dr. Angèle Parent and her team’s research efforts focus on understanding the molecular and cellular mechanisms associated with the development of Alzheimer’s disease (AD). They are using cell culture and mouse models in their research to clarify the role of a genetically engineered protein that may affect the progression of AD. Interestingly, their study identified a novel interaction of a portion of the amyloid precursor protein (APP) that resides inside the cell, termed the “intracellular domain,” with a signaling protein termed the “G-alphaS.” This molecular interaction may impact brain functions such as learning and memory. Indeed, their recent findings demonstrated that membrane accumulation of amyloid precursor protein’s intracellular domain results in inhibition of one of the important signaling cascades associated with AD pathology. Accordingly, in order to prevent or delay AD, these experiments investigate the therapeutic potential of developing a version of the amyloid precursor protein intracellular domain that remains tethered to the cell membrane.
To accomplish this they are using a virus to deliver the modified protein to mice brains. Consequences on brain functions are investigated by examining changes in neuron development and their chemistry. The viral brain administration strategy is the first step toward a comprehensive evaluation of the beneficial effect associated with brain expression of this modified protein. The ultimate goal is to develop novel therapeutic strategies applicable to humans to fight this devastating disorder. Parent and her team are greatly encouraged by their preliminary findings and confident that these investigations will yield significant advances.
Grants
Related Grants
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Alzheimer's Disease Research
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD